Search results
FDA clears GSK's RSV vaccine for adults ages 50-59
United Press International via Yahoo News· 1 hour agoThe U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 23 hours agoTwo other companies – Pfizer and Moderna – also manufacture RSV vaccines approved for adults 60 and...
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Verywell Health via Yahoo News· 3 days agoImportantly, none of the participants experienced Guillain-Barré syndrome (GBS), a rare neurological...
Celebrity doctors promoted Covid vaccine without declaring payments
The Telegraph via Yahoo News· 9 hours agoThe pharmaceutical watchdog has been urged to investigate after a string of celebrity doctors took...
FDA Panel Recommends New COVID Vaccines For JN.1 Lineage By Fall
Forbes· 4 days agoThe FDA’s independent Vaccines and Related Biological Products Advisory Committee voted unanimously...
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 1 day agoThe Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial...
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Clinical Trials Arena via Yahoo Finance· 2 days agoMore choice and tailored vaccine administration According to GlobalData’s pipeline drugs database,...
Analysis | Four questions for today’s Fauci hearing
Washington Post· 5 days agoThe Texas Supreme Court rejected a lawsuit that sought to clarify exceptions to the state’s abortion laws. The longtime infectious-disease expert is back...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 1 day agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
Opinion | Paxlovid Trial Flops for COVID Pneumonia
MedPage Today· 3 days agoIn 2021, nirmatrelvir/ritonavir clearly decreased hospitalization and death among COVID-19 patients who had high risks of severe disease and who had not...